Skip to main content
CCSB logo

CCSB — Investor Relations & Filings

Ticker · 1762 ISIN · TW0001762003 TW Manufacturing
Open in API
Filings indexed 1,610 across all filing types
Latest filing 2019-08-22 Legal Proceedings Report
Country TW Taiwan
Listing TW 1762

About CCSB

www.ccsb.com.tw

Chunghwa Chemical Synthesis & Biotech Co., Ltd. (CCSB) is a specialized manufacturer of Active Pharmaceutical Ingredients (APIs) with a history dating back to 1964. The company focuses on the research, development, and large-scale production of high-quality APIs, particularly in the therapeutic areas of oncology, antifungal treatments, and immunosuppressants. CCSB offers a broad service portfolio that includes cGMP-compliant contract manufacturing and toll manufacturing. By leveraging advanced chemical synthesis and biotechnology platforms, the company provides tailored solutions to global pharmaceutical partners. CCSB adheres to rigorous international quality standards and environmental, health, and safety protocols, ensuring the reliable supply of critical medicinal components for the global healthcare market.

Recent filings

Filing Released Lang Actions
本公司負責人於最高法院107年度台上字第518號案判決書乙事
Legal Proceedings Report Classification · 100% confidence The document is a regulatory announcement from a company regarding a legal proceeding involving the company's chairman. It details a court case and its impact on the company, explicitly mentioning legal events, court decisions, and the company's response. The document is short (837 characters) and does not contain financial statements or detailed financial data. It is not a full audit report or annual report but rather an update on a legal matter. Therefore, it fits the category of Legal Proceedings Report (LTR).
2019-08-22 Chinese
澄清108.08.20經濟日報C6版之報導。
Regulatory Filings Classification · 95% confidence The document is a short announcement (736 characters) from a company clarifying a media report about its business outlook and financial estimates. It explicitly states it is a clarification and refers readers to the company's official disclosures for financial information. There are no financial statements, detailed financial data, or comprehensive reports included. The document is not a full report but a regulatory announcement clarifying information. It fits best under Regulatory Filings (RNS) as a general regulatory announcement and clarification.
2019-08-20 Chinese
108年第2季大陸投資
Regulatory Filings Classification · 95% confidence The document is a tabular disclosure of investment amounts and related financial data concerning investments in mainland China by a Taiwanese listed company. It includes details such as capital amounts, investment methods, cumulative investment amounts, recognized investment gains or losses, and regulatory approval limits. The document is relatively short (1309 characters) and appears to be a regulatory disclosure of investment information rather than a full financial report or earnings release. It does not contain comprehensive financial statements or management discussion. The content aligns with regulatory filings related to investment disclosures, which do not fit into other specific categories like Annual Report, Interim Report, or Earnings Release. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2019-08-14 Chinese
108年第2季海外子公司投資
Interim / Quarterly Report Classification · 85% confidence The document contains financial data related to investment holdings and investment income/losses for a specific period (108年2季, which corresponds to the second quarter of the 108th year in the Taiwanese calendar, roughly 2019). It includes detailed tables of investment amounts, shareholding percentages, and recognized investment gains or losses. The content is substantive financial data for a quarterly period, not just an announcement or a brief summary. The document length is 740 characters, which is short but contains actual financial data, so it is not merely a report publication announcement or a certification. The presence of detailed financial figures and period-specific data indicates this is an Interim / Quarterly Report (IR). H1 2019
2019-08-14 Chinese
108年第2季現金流量表
Interim / Quarterly Report Classification · 95% confidence The document contains a consolidated cash flow statement for the second quarter of the fiscal year 108 (which corresponds to 2019 in the Gregorian calendar). It includes detailed financial data such as cash flows from operating, investing, and financing activities, with specific amounts and accounting items. The presence of actual financial statements for a period shorter than a full fiscal year (half-year or quarterly) indicates this is a comprehensive interim or quarterly financial report. The document length is 2329 characters, which is sufficient to contain substantive financial data, not just an announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2019
2019-08-14 Chinese
108年第2季綜合損益表
Interim / Quarterly Report Classification · 95% confidence The document contains a consolidated comprehensive income statement with detailed financial figures for the second quarter and half-year periods of the fiscal year 108 (Taiwan calendar, corresponding to 2019). It includes revenue, costs, expenses, profits, and earnings per share data. The presence of actual financial data and the coverage of a quarterly period indicate this is a financial report for a period shorter than a full fiscal year. The document length is 3718 characters, which is relatively short but contains substantive financial data, not just an announcement or a certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2019
2019-08-14 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.